Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $85.00. The company’s shares closed last Tuesday at $68.84.
According to TipRanks.com, Yee is a 1-star analyst with an average return of -2.1% and a 42.2% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Olema Pharmaceuticals, and LianBio Sponsored ADR.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $77.31 average price target, which is a 12.3% upside from current levels. In a report issued on January 13, BMO Capital also reiterated a Buy rating on the stock with a $85.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $74.12 and a one-year low of $61.39. Currently, Gilead Sciences has an average volume of 7.36M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
Read More on GILD:
- Analysts Offer Insights on Technology Companies: Logitech (LOGI) and Texas Instruments (TXN)
- Jefferies Keeps a Buy Rating on Xponential Fitness (XPOF)
- Foot Locker (FL) Gets a Buy Rating from Jefferies
- F5 Networks (FFIV) Gets a Hold Rating from Jefferies
- Analysts’ Top Financial Picks: Brown & Brown (BRO), Capital One Financial (COF)
